Vicore to Present at Upcoming Investor Conferences

STOCKHOLM, SE / ACCESSWIRE / November 14, 2024 / Vicore Pharma Holding (STO:VICO)

Stockholm, November 14, 2024 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the following investor conferences:

• Stifel 2024 Healthcare Conference

Location: New York, United States
Presenter: Ahmed Mousa, CEO
Presentation Date and Time: November 18 at 9:10 AM ET/3:10 PM CET
Webcast: https://wsw.com/webcast/stifel96/vico/2103734

• SEB Healthcare Seminar

Location: Stockholm, Sweden
Presenter: Hans Jeppsson, CFO
Presentation Date and Time: November 20 at 4:40 AM ET/10:40 AM CET

• DNB Nordic Healthcare Conference

Location: Oslo, Norway
Presenter: Hans Jeppsson, CFO
Presentation Date and Time: November 26 at 10:15 AM ET/4:15 PM CET

For further information, please contact:
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected]
Hans Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]

This information was submitted for publication on November 14, 2024, at 8:00 CET.

About Vicore Pharma Holding AB
Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) being investigated in a global Phase 2b trial in IPF. Almee™ is an investigational digital therapeutic in clinical development that is based on cognitive behavioral therapy and created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, which the Company believes reflects its potential to have transformative impact. Using its expertise in ATRAG chemistry and biology, Vicore is further developing its pipeline with several new therapies across additional indications. The company's shares are listed on Nasdaq Stockholm's main market (VICO). www.vicorepharma.com

Attachments
Vicore to Present at Upcoming Investor Conferences

SOURCE: Vicore Pharma Holding

You May Also Be Interested In

• Guardian Metal Resources PLC Announces Non-Core Portfolio Exploration Results
• InterContinental Hotels Group PLC Announces Transaction in Own Shares - July 14
• Torex Gold Provides Q2 2026 Morelos Drilling & Exploration Update